Avmapki Fakzynja (avutometinib/defactinib) / Verastem - LARVOL DELTA

AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) U.S. Launch (Businesswire) - "AVMAPKI FAKZYNJA CO-PACK generated net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. Food and Drug Administration (FDA) approval in May 2025..."

Sales • Low Grade Serous Ovarian Cancer